Cargando…

Clinical characteristics and comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems

BACKGROUND: To evaluate the degree to which clinical comorbidities or combinations of comorbidities are associated with SARS-CoV-2 breakthrough infection. MATERIALS AND METHODS: A breakthrough infection was defined as a positive test at least 14 days after a full vaccination regimen. Logistic regres...

Descripción completa

Detalles Bibliográficos
Autores principales: Hogarth, Michael, John, Daniel, Li, Yuxiang, Wang-Rodriguez, Jessica, Chakladar, Jaideep, Li, Wei Tse, Mehta, Sanjay R., Jain, Sharad, Ongkeko, Weg M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155464/
https://www.ncbi.nlm.nih.gov/pubmed/37146904
http://dx.doi.org/10.1016/j.amjms.2023.04.019
_version_ 1785036334157529088
author Hogarth, Michael
John, Daniel
Li, Yuxiang
Wang-Rodriguez, Jessica
Chakladar, Jaideep
Li, Wei Tse
Mehta, Sanjay R.
Jain, Sharad
Ongkeko, Weg M.
author_facet Hogarth, Michael
John, Daniel
Li, Yuxiang
Wang-Rodriguez, Jessica
Chakladar, Jaideep
Li, Wei Tse
Mehta, Sanjay R.
Jain, Sharad
Ongkeko, Weg M.
author_sort Hogarth, Michael
collection PubMed
description BACKGROUND: To evaluate the degree to which clinical comorbidities or combinations of comorbidities are associated with SARS-CoV-2 breakthrough infection. MATERIALS AND METHODS: A breakthrough infection was defined as a positive test at least 14 days after a full vaccination regimen. Logistic regression was used to calculate aORs, which were adjusted for age, sex, and race information. RESULTS: A total of 110,380 patients from the UC CORDS database were included. After adjustment, stage 5 CKD due to hypertension (aOR: 7.33; 95% CI: 4.86-10.69; p<.001; power=1) displayed higher odds of infection than any other comorbidity. Lung transplantation history (aOR: 4.79; 95% CI: 3.25-6.82; p<.001; power= 1), coronary atherosclerosis (aOR: 2.12; 95% CI: 1.77-2.52; p<.001; power=1), and vitamin D deficiency (aOR: 1.87; 95% CI: 1.69-2.06; p<.001; power=1) were significantly correlated to breakthrough infection. Patients with obesity in addition to essential hypertension (aOR: 1.74; 95% CI: 1.51-2.01; p<.001; power=1) and anemia (aOR: 1.80; 95% CI: 1.47-2.19; p<.001; power=1) were at additional risk of breakthrough infection compared to those with essential hypertension and anemia alone. CONCLUSIONS: Further measures should be taken to prevent breakthrough infection for individuals with these conditions, such as acquiring additional doses of the SARS-CoV-2 vaccine to boost immunity.
format Online
Article
Text
id pubmed-10155464
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation.
record_format MEDLINE/PubMed
spelling pubmed-101554642023-05-03 Clinical characteristics and comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems Hogarth, Michael John, Daniel Li, Yuxiang Wang-Rodriguez, Jessica Chakladar, Jaideep Li, Wei Tse Mehta, Sanjay R. Jain, Sharad Ongkeko, Weg M. Am J Med Sci Clinical Investigation BACKGROUND: To evaluate the degree to which clinical comorbidities or combinations of comorbidities are associated with SARS-CoV-2 breakthrough infection. MATERIALS AND METHODS: A breakthrough infection was defined as a positive test at least 14 days after a full vaccination regimen. Logistic regression was used to calculate aORs, which were adjusted for age, sex, and race information. RESULTS: A total of 110,380 patients from the UC CORDS database were included. After adjustment, stage 5 CKD due to hypertension (aOR: 7.33; 95% CI: 4.86-10.69; p<.001; power=1) displayed higher odds of infection than any other comorbidity. Lung transplantation history (aOR: 4.79; 95% CI: 3.25-6.82; p<.001; power= 1), coronary atherosclerosis (aOR: 2.12; 95% CI: 1.77-2.52; p<.001; power=1), and vitamin D deficiency (aOR: 1.87; 95% CI: 1.69-2.06; p<.001; power=1) were significantly correlated to breakthrough infection. Patients with obesity in addition to essential hypertension (aOR: 1.74; 95% CI: 1.51-2.01; p<.001; power=1) and anemia (aOR: 1.80; 95% CI: 1.47-2.19; p<.001; power=1) were at additional risk of breakthrough infection compared to those with essential hypertension and anemia alone. CONCLUSIONS: Further measures should be taken to prevent breakthrough infection for individuals with these conditions, such as acquiring additional doses of the SARS-CoV-2 vaccine to boost immunity. The Authors. Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation. 2023-05-03 /pmc/articles/PMC10155464/ /pubmed/37146904 http://dx.doi.org/10.1016/j.amjms.2023.04.019 Text en © 2023 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Clinical Investigation
Hogarth, Michael
John, Daniel
Li, Yuxiang
Wang-Rodriguez, Jessica
Chakladar, Jaideep
Li, Wei Tse
Mehta, Sanjay R.
Jain, Sharad
Ongkeko, Weg M.
Clinical characteristics and comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems
title Clinical characteristics and comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems
title_full Clinical characteristics and comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems
title_fullStr Clinical characteristics and comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems
title_full_unstemmed Clinical characteristics and comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems
title_short Clinical characteristics and comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems
title_sort clinical characteristics and comorbidities associated with sars-cov-2 breakthrough infection in the university of california healthcare systems
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155464/
https://www.ncbi.nlm.nih.gov/pubmed/37146904
http://dx.doi.org/10.1016/j.amjms.2023.04.019
work_keys_str_mv AT hogarthmichael clinicalcharacteristicsandcomorbiditiesassociatedwithsarscov2breakthroughinfectionintheuniversityofcaliforniahealthcaresystems
AT johndaniel clinicalcharacteristicsandcomorbiditiesassociatedwithsarscov2breakthroughinfectionintheuniversityofcaliforniahealthcaresystems
AT liyuxiang clinicalcharacteristicsandcomorbiditiesassociatedwithsarscov2breakthroughinfectionintheuniversityofcaliforniahealthcaresystems
AT wangrodriguezjessica clinicalcharacteristicsandcomorbiditiesassociatedwithsarscov2breakthroughinfectionintheuniversityofcaliforniahealthcaresystems
AT chakladarjaideep clinicalcharacteristicsandcomorbiditiesassociatedwithsarscov2breakthroughinfectionintheuniversityofcaliforniahealthcaresystems
AT liweitse clinicalcharacteristicsandcomorbiditiesassociatedwithsarscov2breakthroughinfectionintheuniversityofcaliforniahealthcaresystems
AT mehtasanjayr clinicalcharacteristicsandcomorbiditiesassociatedwithsarscov2breakthroughinfectionintheuniversityofcaliforniahealthcaresystems
AT jainsharad clinicalcharacteristicsandcomorbiditiesassociatedwithsarscov2breakthroughinfectionintheuniversityofcaliforniahealthcaresystems
AT ongkekowegm clinicalcharacteristicsandcomorbiditiesassociatedwithsarscov2breakthroughinfectionintheuniversityofcaliforniahealthcaresystems